Spinal Metastasis
Conditions
Brief summary
This study will compare pain (primary end-point) and local metastatic tumor control (secondary end-point) after dose-intensified image-guided fractionated stereotactic body radiation therapy (SBRT) for painful mass-type spinal metastases versus conventional radiation therapy.
Detailed description
Rationale: Radiation therapy is an effective palliative treatment for painful spinal metastases. A sub-group of patients with mass-type spinal metastases, a factor associated with poor local metastasis control, require treatment optimization ensuring durable pain control and metastatic tumor control. Proposed solution: To intensify (escalate) radiation dose using simultaneous integrated boost with image-guided hypofractionated SBRT for painful mass-type spinal metastases in a randomized controlled trial. Two experimental fractionation regimes will be tested in the study depending on presence or absence of epidural involvement. Dose intensification is expected to achieve long-term pain control and long-term palliation as well as long-term local metastatic tumor control without adding toxicity as compared to conventional fractionation regimes with conventional radiation therapy. The study will be carried out as multinational, multicentre phase II clinical controlled trial enrolling patients with painful mass-type spinal metastases who are eligible for radiation therapy without surgery. This study additionally includes a prospective observational arm for patients not eligible for randomisation who are treated in analogy to arm A of the randomised arm.
Interventions
RADIATIONdose-intensified image-guided SBRT using simultaneous integrated boost
RADIATIONExternal 3-dimensional conformal radiotherapy (3D-CRT)
Sponsors
University of Zurich
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Established histological diagnosis of a malignant primary or metastatic tumor; * Histologically, radiologically or scintigraphically proven spinal metastasis; * Pain in the affected spinal region or free of pain under pain medication; * Age ≥18 years old; * Karnofsky performance status ≥60%; * Written informed consent.
Exclusion criteria
* Modified Bauer Score \< 2; * No-mass-type metastatic lesion, defined as a 3D space-occupying lesion visible on CT and/or MR; * "Radiosensitive" histology of the primary tumor, e.g., lymphoma, small-cell lung cancer, multiple myeloma, germ cell tumors; * Progressive neurological symptoms/deficit; * More than 3 affected vertebrae in one target site; * More than 2 treatment sites; * Spinal Instability Neoplastic Score (SINS) 13 - 18, i.e., unstable; * Unable to tolerate treatment (unable to lie flat and immobilized); * Previous radiotherapy of the region at the level of the affected vertebrae; * Previous radionuclide therapy within 30 days before stereotactic body radiation therapy; * Previous surgery (stabilization) of the affected vertebrae; * Contraindications for MR scanning, e.g., pacemakers; * Patients with allergy to contrast agents used in computer tomography (CT) and magnetic resonance (MR) imaging or patients who cannot be premedicated to use contrast agent; * Pregnant or lactating women; * Women of child bearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment; * Mental conditions rendering the patient unable to understand the nature, scope, and possible consequences of the study; * Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain response - improvement by ≥ 2 points on the pain Visual Analogue Scale at 6 months post-treatment at the treatment site | 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local metastasis control | up to 2 years | Local metastasis control is defined from the day of randomization to a day of local (at the site of the treated spinal metastasis) progression, i.e. local failure, determined on control MR images as a change in signal intensity or on CT images as increasing soft-tissue mass. Increased epidural disease or enlargement of paraspinal disease on control images will be documented as progression. |
| Acute and late toxicity | Acute toxicity: up to 3 months; late toxicity: from 3 months up to 24 months | Acute aund late toxicity will be assessed in accordance to NCI CTCEA version 4.03 criteria. |
| Cancer-specific survival | up to 2 years | Cancer-specific survival is defined from the day of randomization to a day of death due to cancer progression. |
| Quality-of-life (QoL) | Day 1 and last day of treatment (usually day5 if Radiotherapy is delivered in 5 fractions, and day 12 if Radiotherapy is delivered in 10 fractions); months 1, 3, 6, 9, 12, 18 and 24 | Quality-of-life (QoL) as measured by the EORTC QLQ-C15-PL, EORTC-BM22 and EQ-5D-5L patient reported questionnaires |
| Epidural spinal cord compression | up to 2 years | Epidural spinal cord compression (ESCC) will be scored using Bilsky criteria. |
| Overall survival | up to 2 years | Overall survival is defined from the day of randomization to a day of death of any cause. |
Countries
Switzerland
Contacts
PRINCIPAL_INVESTIGATORMatthias Guckenberger, Prof. Dr.
Universitätsspital Zürich
Outcome results
None listed